Colchicine drug-to-drug interactions
The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.
1. A method of treating a colchicine sensitive disorder, comprising orally administering a pharmaceutical composition comprising a liquid colchicine solution to a human subject having a colchicine sensitive disorder selected from gout, familial Mediterranean fever (FMF), pericarditis, Behçet's disease, atrial fibrillation, amyloidosis, calcium pyrophosphate deposition disease (pseudogout), cirrhosis of the liver, and sarcoid arthritis in an effective amount to treat the disorder,
wherein the pharmaceutical composition comprising the liquid colchicine solution comprises 0.01-1.0 mg/ml colchicine, anhydrous citric acid, dibasic sodium phosphate heptahydrate, a thickening agent, a preservative, propylene glycol, glycerin, and water and has a viscosity of 40-800 cps, and is stable for at least 1 month at refrigerated, ambient, and accelerated temperature conditions.
2. The method of claim 1 , wherein the colchicine sensitive disorder is gout.
3. The method of claim 1 , wherein the pharmaceutical composition comprising the liquid colchicine solution comprises 0.05-0.25 mg/mL colchicine.
4. The method of claim 1 , wherein the pharmaceutical composition comprising the liquid colchicine solution comprises 0.12 mg/mL colchicine.
5. The method of claim 1 , wherein the viscosity is 80-250 cps.
6. The method of claim 1 , wherein the pharmaceutical composition comprising the liquid colchicine solution is stable for at least 3 months at refrigerated, ambient, and accelerated temperature conditions.
7. The method of claim 1 , wherein the pharmaceutical composition comprising the liquid colchicine solution further comprises a sweetener, a flavoring agent, a coloring agent, or any combination thereof.
8. The method of claim 1 , wherein the pharmaceutical composition comprising the liquid colchicine solution further comprises a CYP3A4 inhibitor or a P-glycoprotein inhibitor.
9. The method of claim 1 , wherein a daily dosage of colchicine is 0.5-2.4 mg per day.
10. A method of preventing gout flares, comprising orally administering to a human subject in need thereof a pharmaceutical composition comprising a liquid colchicine solution in an effective amount to prevent gout flares,
wherein the pharmaceutical composition comprising the liquid colchicine solution comprises 0.01-1.0 mg/ml colchicine, anhydrous citric acid, dibasic sodium phosphate heptahydrate, a thickening agent, a preservative, propylene glycol, glycerin, and water, and has a viscosity of 40-800 cps, and is stable for at least 1 month at refrigerated, ambient, and accelerated temperature conditions.
11. The method of claim 10 , wherein the subject has a history of gout flares.
12. The method of claim 10 , wherein the pharmaceutical composition comprising the liquid colchicine solution comprises 0.05-0.25 mg/mL colchicine.
13. The method of claim 10 , wherein the pharmaceutical composition comprising the liquid colchicine solution comprises 0.12 mg/mL colchicine.
14. The method of claim 10 , wherein the viscosity of the pharmaceutical composition comprising the liquid colchicine solution is 80-250 cps.
15. The method of claim 10 , wherein the pharmaceutical composition comprising the liquid colchicine solution is stable for at least 3 months at refrigerated, ambient, and accelerated temperature conditions.
16. The method of claim 10 , wherein the pharmaceutical composition comprising the liquid colchicine solution further comprises a sweetener, a flavoring agent, a coloring agent, or any combination thereof.
17. The method of claim 10 , wherein the pharmaceutical composition comprising the liquid colchicine solution further comprises a CYP3A4 inhibitor or a P-glycoprotein inhibitor.
18. The method of claim 10 , wherein a daily dosage of colchicine is 0.5-2.4 mg per day.